Therefore, EGFR reactivation limits the efficacy of KRAS G12C inhibition in CRC, while its blockade with a combined KRAS G12C inhibitor and anti-EGFR approach might be effective in overcoming this adaptive resistance [72]. Here, KRAS is linked to colorectal carcinoma.